

Tobias Klatte

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4498761/tobias-klatte-publications-by-citations.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

175
papers

5,290
citations

39
h-index

65
g-index

200
ext. papers

6,550
ext. citations

4.6
avg, IF

5.52
L-index

#	Paper	IF	Citations
175	Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. <i>Nature</i> , 2015 , 521, 94-8	50.4	313
174	Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. <i>Cancer</i> , 2007 , 109, 2257-67	6.4	298
173	Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 746-53	2.2	164
172	Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. <i>Clinical Cancer Research</i> , 2007 , 13, 7388-93	2.3	152
171	A Literature Review of Renal Surgical Anatomy and Surgical Strategies for Partial Nephrectomy. <i>European Urology</i> , 2015 , 68, 980-92	10.2	147
170	Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. <i>Clinical Cancer Research</i> , 2009 , 15, 1162-9	12.9	139
169	Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. <i>International Journal of Cancer</i> , 2008 , 123, 395-400	7.5	134
168	Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 894-900	4	133
167	Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. <i>Journal of Urology</i> , 2008 , 179, 1719-26	2.5	125
166	Epidemiology and screening for renal cancer. <i>World Journal of Urology</i> , 2018 , 36, 1341-1353	4	106
165	The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. <i>Journal of Urology</i> , 2008 , 179, 61-6	2.5	98
164	Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time. <i>European Urology</i> , 2014 , 66, 361-70	10.2	94
163	Laparoscopic cryoablation versus partial nephrectomy for the treatment of small renal masses: systematic review and cumulative analysis of observational studies. <i>European Urology</i> , 2011 , 60, 435-43	10.2	85
162	Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. <i>Journal of Urology</i> , 2013 , 190, 1999-2004	2.5	83
161	Prognostic factors and prognostic models for renal cell carcinoma: a literature review. <i>World Journal of Urology</i> , 2018 , 36, 1943-1952	4	78
160	Systematic review and meta-analysis of perioperative and oncologic outcomes of laparoscopic cryoablation versus laparoscopic partial nephrectomy for the treatment of small renal tumors. <i>Journal of Urology</i> , 2014 , 191, 1209-17	2.5	74
159	Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. <i>Cancer</i> , 2009 , 115, 1448-58	6.4	74

158	Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. <i>Cancer</i> , 2012 , 118, 82-90.	6.4	69
157	Hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinomas and oncocytomas have excellent oncologic outcomes. <i>European Urology</i> , 2010 , 57, 661-5	10.2	66
156	Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis. <i>American Journal of Clinical Pathology</i> , 2012 , 137, 761-8	1.9	62
155	Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. <i>Cancer</i> , 2010 , 116, 4696-702	6.4	59
154	Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma. <i>BJU International</i> , 2007 , 99, 821-4	5.6	59
153	Outcomes of minimally invasive simple prostatectomy for benign prostatic hyperplasia: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2015 , 33, 563-70	4	58
152	Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. <i>Journal of Urology</i> , 2009 , 181, 1558-64; discussion 1563-4	2.5	58
151	Pathobiology and prognosis of chromophobe renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008 , 26, 604-9	2.8	56
150	Comparison of the prognostic value of pretreatment measurements of systemic inflammatory response in patients undergoing curative resection of clear cell renal cell carcinoma. <i>World Journal of Urology</i> , 2015 , 33, 2045-52	4	55
149	Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience. <i>BJU International</i> , 2007 , 100, 21-5	5.6	54
148	Surveillance for renal cell carcinoma: why and how? When and how often?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008 , 26, 550-4	2.8	53
147	External validation of the preoperative anatomical classification for prediction of complications related to nephron-sparing surgery. <i>World Journal of Urology</i> , 2010 , 28, 531-5	4	52
146	Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC). <i>BJU International</i> , 2013 , 111, E348-53	5.6	51
145	Gender differences in incidence and outcomes of urothelial and kidney cancer. <i>Nature Reviews Urology</i> , 2015 , 12, 585-92	5.5	49
144	The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 68.e1-7	2.8	49
143	Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. <i>Journal of Urology</i> , 2007 , 178, 35-40; discussion 40	2.5	47
142	Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 335-341	2.8	45
141	Features and outcomes of renal cell carcinoma of native kidneys in renal transplant recipients. <i>BJU International</i> , 2010 , 105, 1260-5	5.6	45

140	Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma. <i>Cancer</i> , 2013 , 119, 1547-54	6.4	44
139	Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval. <i>Journal of Urology</i> , 2007 , 177, 2081-6; discussion 2086-7	2.5	42
138	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. <i>European Urology</i> , 2021 , 79, 339-342	10.2	42
137	Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 483.e17-483.e24	2.8	40
136	Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. <i>Genome Medicine</i> , 2020 , 12, 23	14.4	37
135	Preoperative serum cholesterol is an independent prognostic factor for patients with renal cell carcinoma (RCC). <i>BJU International</i> , 2015 , 115, 397-404	5.6	37
134	Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma. <i>Cancer</i> , 2012 , 118, 5777-82	6.4	37
133	Perioperative, oncologic, and functional outcomes of laparoscopic renal cryoablation and open partial nephrectomy: a matched pair analysis. <i>Journal of Endourology</i> , 2011 , 25, 991-7	2.7	37
132	Impact of Resection Technique on Perioperative Outcomes and Surgical Margins after Partial Nephrectomy for Localized Renal Masses: A Prospective Multicenter Study. <i>Journal of Urology</i> , 2020 , 203, 496-504	2.5	37
131	Suture techniques during laparoscopic and robot-assisted partial nephrectomy: a systematic review and quantitative synthesis of peri-operative outcomes. <i>BJU International</i> , 2019 , 123, 923-946	5.6	36
130	Aurora A Kinase as a diagnostic urinary marker for urothelial bladder cancer. <i>World Journal of Urology</i> , 2015 , 33, 105-10	4	34
129	Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features. <i>Journal of Urology</i> , 2011 , 185, 30-5	2.5	34
128	The contemporary role of ablative treatment approaches in the management of renal cell carcinoma (RCC): focus on radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), and cryoablation. <i>World Journal of Urology</i> , 2014 , 32, 597-605	4	33
127	Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma. <i>Journal of Urology</i> , 2010 , 184, 53-8	2.5	33
126	Interpersonal variability and present diagnostic dilemmas in Bosniak classification system. <i>Scandinavian Journal of Urology and Nephrology</i> , 2011 , 45, 239-44		33
125	The effect of gender and age on kidney cancer survival: younger age is an independent prognostic factor in women with renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 30.e9-13	2.8	31
124	Prospective external validation of a bladder cancer detection model. <i>Journal of Urology</i> , 2014 , 192, 1343-8		30
123	The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis. <i>European Urology Focus</i> , 2016 , 2, 79-85	5.1	29

122	European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update.. <i>European Urology</i> , 2022 ,	10.2	29
121	Management, pathology and outcomes of Bosniak category IIF and III cystic renal lesions. <i>World Journal of Urology</i> , 2015 , 33, 295-300	4	28
120	A urinary microRNA (miR) signature for diagnosis of bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 531.e1-531.e8	2.8	28
119	Molecular biology of renal cortical tumors. <i>Urologic Clinics of North America</i> , 2008 , 35, 573-80; vi	2.9	27
118	Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 71.e21-6	2.8	26
117	The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. <i>BJU International</i> , 2015 , 116, 72-8	5.6	26
116	Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinoma. <i>Journal of Urology</i> , 2010 , 183, 2143-7	2.5	26
115	Absent CD44v6 expression is an independent predictor of poor urothelial bladder cancer outcome. <i>Journal of Urology</i> , 2010 , 183, 2403-8	2.5	26
114	High-intensity focused ultrasound for the treatment of renal masses: current status and future potential. <i>Current Opinion in Urology</i> , 2009 , 19, 188-91	2.8	26
113	Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma. <i>European Urology</i> , 2012 , 61, 888-95	10.2	25
112	Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e267-e273	2.3	25
111	Association of human telomerase reverse transcriptase gene polymorphisms, serum levels, and telomere length with renal cell carcinoma risk and pathology. <i>Molecular Carcinogenesis</i> , 2016 , 55, 1458-65	5	25
110	Genomics and clinical correlates of renal cell carcinoma. <i>World Journal of Urology</i> , 2018 , 36, 1899-1911	4	24
109	Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib. <i>Cancer Biology and Therapy</i> , 2014 , 15, 1239-47	4.6	24
108	Renal cell carcinoma of native kidneys in renal transplant patients. <i>Current Opinion in Urology</i> , 2011 , 21, 376-9	2.8	24
107	Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer. <i>European Urology</i> , 2015 , 68, 552-4	10.2	22
106	Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer. <i>Journal of Urology</i> , 2014 , 191, 1238-43	2.5	22
105	ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy. <i>Journal of Urology</i> , 2015 , 194, 1456-62	2.5	22

104	Latest Evidence on the Impact of Smoking, Sports, and Sexual Activity as Modifiable Lifestyle Risk Factors for Prostate Cancer Incidence, Recurrence, and Progression: A Systematic Review of the Literature by the European Association of Urology Section of Oncological Urology (ESOU). <i>European Urology Focus</i> , 2019 , 5, 756-787	5.1	22
103	Insulin-like growth factor messenger RNA-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma. <i>European Urology</i> , 2014 , 66, 379-85	10.2	21
102	Understanding the natural biology of kidney cancer: implications for targeted cancer therapy. <i>Reviews in Urology</i> , 2007 , 9, 47-56	1	21
101	Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?. <i>Cancers</i> , 2019 , 11,	6.6	20
100	Oncologic Outcomes of Kidney Sparing Surgery versus Radical Nephroureterectomy for the Elective Treatment of Clinically Organ Confined Upper Tract Urothelial Carcinoma of the Distal Ureter. <i>Journal of Urology</i> , 2016 , 195, 1354-1361	2.5	20
99	A prospective study on surgical-site infections in thyroid operation. <i>Surgery</i> , 2014 , 155, 675-81	3.6	20
98	Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 625-30	2.8	20
97	Increase of papillary thyroid microcarcinoma and a plea for restrictive treatment: A retrospective study of 1,391 prospective documented patients. <i>Surgery</i> , 2016 , 159, 503-11	3.6	19
96	Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 233.e1-6	2.8	19
95	Renal cell carcinoma Fuhrman grade and histological subtype correlate with complete polymorphic deletion of glutathione S-transferase M1 gene. <i>Journal of Urology</i> , 2010 , 183, 878-83	2.5	19
94	Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease. <i>PLoS ONE</i> , 2017 , 12, e0184173	3.7	19
93	Systematic Review and Pooled Analysis of the Impact of Renorrhaphy Techniques on Renal Functional Outcome After Partial Nephrectomy. <i>European Urology Oncology</i> , 2019 , 2, 572-575	6.7	18
92	Complex renal cystic masses: current standards and controversies. <i>International Urology and Nephrology</i> , 2012 , 44, 13-8	2.3	17
91	The CASP8 -652 6N insertion/deletion promoter polymorphism is associated with renal cell carcinoma risk and metastasis. <i>Journal of Urology</i> , 2013 , 190, 717-22	2.5	17
90	Development of a Preoperative Nomogram Incorporating Biomarkers of Systemic Inflammatory Response to Predict Nonorgan-confined Urothelial Carcinoma of the Bladder at Radical Cystectomy. <i>Urology</i> , 2016 , 95, 132-8	1.6	17
89	Impact of Metabolic Diseases, Drugs, and Dietary Factors on Prostate Cancer Risk, Recurrence, and Survival: A Systematic Review by the European Association of Urology Section of Oncological Urology. <i>European Urology Focus</i> , 2019 , 5, 1029-1057	5.1	17
88	Preoperative nomogram to predict the likelihood of complications after radical nephroureterectomy. <i>BJU International</i> , 2017 , 119, 268-275	5.6	16
87	Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting. <i>World Journal of Urology</i> , 2018 , 36, 417-425	4	16

86	Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice. <i>BJU International</i> , 2018 , 121, 84-92	5.6	16
85	Evaluation of ABO blood group as a prognostic marker in renal cell carcinoma (RCC). <i>BJU International</i> , 2014 , 113, E62-6	5.6	15
84	Surgical Management and Outcomes of Renal Tumors Arising from Horseshoe Kidneys: Results from an International Multicenter Collaboration. <i>European Urology</i> , 2021 , 79, 133-140	10.2	15
83	The protease activated receptor 1 gene variation IVSn -14 A>T is associated with distant metastasis and cancer specific survival in renal cell carcinoma. <i>Journal of Urology</i> , 2013 , 190, 1392-7	2.5	14
82	The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 151.e17-151.e23	2.8	13
81	Surgical Management of Adrenocortical Carcinoma: Impact of Laparoscopic Approach, Lymphadenectomy, and Surgical Volume on Outcomes-A Systematic Review and Meta-analysis of the Current Literature. <i>European Urology Focus</i> , 2016 , 1, 241-250	5.1	13
80	The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort. <i>BMC Medicine</i> , 2019 , 17, 182	11.4	13
79	Transperineal template-guided biopsy for diagnosis of prostate cancer in patients with at least two prior negative biopsies. <i>Wiener Klinische Wochenschrift</i> , 2013 , 125, 669-73	2.3	13
78	The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder. <i>BJU International</i> , 2008 , 101 Suppl 4, 45-8	5.6	13
77	Associations between presenting symptoms, clinicopathological parameters, and prognosis in a contemporary series of patients with renal cell carcinoma. <i>Korean Journal of Urology</i> , 2014 , 55, 505-10		12
76	Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study. <i>BJU International</i> , 2017 , 119, 234-238	5.6	11
75	Perioperative Allogenic Blood Transfusion in Renal Cell Carcinoma: Risk Factors and Effect on Long-term Outcomes. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e421-e427	3.3	11
74	Magnetic resonance imaging as an adjunct diagnostic tool in computed tomography defined Bosniak IIF-III renal cysts: a multicenter study. <i>World Journal of Urology</i> , 2018 , 36, 905-911	4	11
73	Dynamic Prognostication Using Conditional Recurrence and Progression Estimates for Patients with Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2016 , 196, 46-51	2.5	11
72	Quality of life outcomes in patients with localised renal cancer: a literature review. <i>World Journal of Urology</i> , 2018 , 36, 1961-1972	4	11
71	Age-specific PCA3 score reference values for diagnosis of prostate cancer. <i>World Journal of Urology</i> , 2012 , 30, 405-10	4	11
70	Sex, age, and surgeon decision on nephron-sparing surgery are independent predictors of renal masses with benign histologic findings--a multicenter survey. <i>Urology</i> , 2010 , 76, 541-6	1.6	11
69	Metastatic melanoma to the kidney presenting with renal vein tumor thrombus. <i>Urology</i> , 2007 , 69, 982.e7-9		11

68	Update on ablative therapies of renal tumors. <i>Current Opinion in Urology</i> , 2016 , 26, 410-6	2.8	11
67	The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 533.e1-533.e10	2.8	11
66	Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 495.e15-22	2.8	10
65	Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data. <i>European Urology Oncology</i> , 2020 , 3, 168-173	6.7	9
64	Gender differences in benign renal masses. <i>World Journal of Urology</i> , 2013 , 31, 1051-7	4	9
63	Serum Adiponectin Predicts Cancer-specific Survival of Patients with Renal Cell Carcinoma. <i>European Urology Focus</i> , 2016 , 2, 197-203	5.1	9
62	Do We Truly Care About the Functional Outcomes for Renal Cancer Patients? Multidisciplinarity Is Still Far Away. <i>European Urology</i> , 2019 , 75, 349-350	10.2	9
61	Elevated preoperative neutrophil-lymphocyte ratio predicts upgrading at radical prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2018 , 21, 100-105	6.2	9
60	Impact of Intra- and Postoperative Blood Transfusion on the Incidence, Timing, and Pattern of Disease Recurrence After Radical Cystectomy. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e681-e688	3.3	8
59	Novel biomarkers to predict response and prognosis in localized bladder cancer. <i>Urologic Clinics of North America</i> , 2015 , 42, 225-33, ix	2.9	8
58	The Role of Ablation and Minimally Invasive Techniques in the Management of Small Renal Masses. <i>European Urology Oncology</i> , 2018 , 1, 395-402	6.7	8
57	Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 460.e1-460.e8	2.8	7
56	Does the Unexpected Presence of Non-organ-confined Disease at Final Pathology Undermine Cancer Control in Patients with Clinical T1N0M0 Renal Cell Carcinoma Who Underwent Partial Nephrectomy?. <i>European Urology Focus</i> , 2018 , 4, 972-977	5.1	7
55	Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2016 , 34, 1411-9	4	7
54	Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer. <i>Urologia Internationalis</i> , 2018 , 101, 197-200	1.9	7
53	Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC). <i>European Urology Oncology</i> , 2021 , 4, 256-263	6.7	7
52	The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium. <i>European Urology Oncology</i> , 2021 , 4, 473-482	6.7	7
51	A Decision Analysis Evaluating Screening for Kidney Cancer Using Focused Renal Ultrasound. <i>European Urology Focus</i> , 2021 , 7, 407-419	5.1	7

50	A practical guide and decision-making protocol for the management of complex renal cystic masses. <i>Arab Journal of Urology Arab Association of Urology</i> , 2017 , 15, 115-122	1.7	6
49	Histopathology and prognosis of de novo bladder tumors following solid organ transplantation. <i>World Journal of Urology</i> , 2015 , 33, 2087-93	4	6
48	Intravesical bacillus Calmette-Guérin instillation therapy for non-muscle-invasive bladder cancer following solid organ transplantation. <i>Wiener Klinische Wochenschrift</i> , 2013 , 125, 189-95	2.3	6
47	Chronic Kidney Disease After Partial Nephrectomy in Patients With Preoperative Inconspicuous Renal Function - Curiosity or Relevant Issue?. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, e754-e761	3.3	6
46	Chest computed tomography for staging renal tumours: validation and simplification of a risk prediction model from a large contemporary retrospective cohort. <i>BJU International</i> , 2020 , 125, 561-567 ^{5.6}	5.6	5
45	p53-expression in patients with renal cell carcinoma correlates with a higher probability of disease progression and increased cancer-specific mortality after surgery but does not enhance the predictive accuracy of robust outcome models. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 26, 21-15, 21-21	2.8	5
44	HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas. <i>Pathology and Oncology Research</i> , 2018 , 24, 575-581	2.6	5
43	External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2018 , 36, 1973-1980	4	5
42	Differential diagnosis of hypercalcemia in renal malignancy. <i>Urology</i> , 2007 , 70, 179.e7-8	1.6	5
41	Impact of frailty on perioperative and oncologic outcomes in patients undergoing surgery or ablation for renal cancer: a systematic review. <i>Minerva Urology and Nephrology</i> , 2021 ,	2.3	5
40	Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e92-e99	3.3	5
39	Clinical, surgical, pathological and follow-up features of kidney cancer patients with Von Hippel-Lindau syndrome: novel insights from a large consortium. <i>World Journal of Urology</i> , 2021 , 39, 2969-2975	4	5
38	Prognostic and discriminative power of the 7th TNM classification for patients with surgically treated papillary renal cell carcinoma: results of a multi-institutional validation study (CORONA subtype project). <i>Scandinavian Journal of Urology</i> , 2017 , 51, 269-276	1.6	4
37	Characterization of Late Recurrence After Radical Cystectomy in a Large Multicenter Cohort of Bladder Cancer Patients. <i>Urology</i> , 2017 , 106, 119-124	1.6	4
36	Urinary expression of genes involved in DNA methylation and histone modification for diagnosis of bladder cancer in patients with asymptomatic microscopic haematuria. <i>Oncology Letters</i> , 2019 , 18, 57-62 ^{2.6}	2.6	4
35	Acceptance of Adjuvant and Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer in Germany: A Survey of Current Practice. <i>Urologia Internationalis</i> , 2018 , 101, 25-30	1.9	4
34	Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. <i>World Journal of Urology</i> , 2016 , 34, 1155-61	4	4
33	Effect of Stage Migration on Bladder Cancer: A Slow but Steady Improvement in Long-Term Survival Rates After Radical Cystectomy in Previous 25 Years. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e223-e228	3.3	4

32	Partial nephrectomy driven by cavitron ultrasonic surgical aspirator under zero ischemia: a pilot study. <i>World Journal of Urology</i> , 2015 , 33, 2015-21	4	4
31	2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma.. <i>European Urology</i> , 2021 ,	10.2	4
30	Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy?. <i>BJU International</i> , 2021 , 128, 386-394	5.6	4
29	Non-Muscle-Invasive Bladder Cancer in the Elderly Patient. <i>Current Geriatrics Reports</i> , 2014 , 3, 42-47	1.3	3
28	Risk models for recurrence and survival after kidney cancer: a systematic review.. <i>BJU International</i> , 2021 ,	5.6	3
27	Reproducibility of CT-based radiomic features against image resampling and perturbations for tumour and healthy kidney in renal cancer patients. <i>Scientific Reports</i> , 2021 , 11, 11542	4.9	3
26	Work-up of the Incidental Adrenal Mass. <i>European Urology Focus</i> , 2016 , 1, 217-222	5.1	3
25	Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 356-362 ^{2.8}	2.8	2
24	Intraoperative imprint cytology for real-time assessment of surgical margins during partial nephrectomy: A comparison with frozen section. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 67.e25-9	2.8	2
23	Words of wisdom. Re: radical prostatectomy or watchful waiting in early prostate cancer. <i>European Urology</i> , 2014 , 66, 386-7	10.2	2
22	Organ Preservation Is Less Frequently Performed in Women Surgically Treated for Papillary Renal Cell Carcinoma-Results of a Comprehensive Multicenter Study. <i>Urology</i> , 2017 , 109, 107-114	1.6	2
21	Intermediate- and long-term oncological outcomes of active surveillance for localized renal masses: a systematic review and quantitative analysis. <i>BJU International</i> , 2021 , 128, 131-143	5.6	2
20	External validation of a postoperative nomogram for the prediction of disease-specific survival in patients with papillary renal cell carcinoma using a large multicenter database. <i>International Journal of Clinical Oncology</i> , 2020 , 25, 145-150	4.2	2
19	Standard Semen Parameters Sperm Kinematics to Predict Sperm DNA Damage. <i>World Journal of Men's Health</i> , 2021 , 39, 116-122	6.8	2
18	Reply by Authors. <i>Journal of Urology</i> , 2020 , 203, 503-504	2.5	1
17	The 1999 and 2010 WHO reference values for human semen analysis to predict sperm DNA damage: A comparative study. <i>Reproductive Biology</i> , 2020 , 20, 379-383	2.3	1
16	Incidence and preoperative predictors for major complications following radical nephroureterectomy. <i>Translational Andrology and Urology</i> , 2020 , 9, 1786-1793	2.3	1
15	Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma. <i>World Journal of Urology</i> , 2021 , 39, 3823-3831	4	1

14	Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patients. <i>World Journal of Urology</i> , 2020 , 38, 1525-1533	4	1
13	Outcome after resection of occult and non-occult lymph node metastases at the time of nephrectomy. <i>World Journal of Urology</i> , 2021 , 39, 3377-3383	4	1
12	Impact of Trifecta definition on rates and predictors of "successful" robotic partial nephrectomy for localized renal masses: results from the Surface-Intermediate-Base Margin Score International Consortium.. <i>Minerva Urology and Nephrology</i> , 2022 , 74, 186-193	2.3	1
11	Editorial comment. <i>Journal of Urology</i> , 2009 , 182, 2606	2.5	0
10	Thioredoxin 1 (Trx1) is associated with poor prognosis in clear cell renal cell carcinoma (ccRCC): an example for the crucial role of redox signaling in ccRCC. <i>World Journal of Urology</i> , 2021 , 40, 739	4	0
9	Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration.. <i>World Journal of Urology</i> , 2022 , 1	4	0
8	Re: Adjuvant Sunitinib in High-risk Renal-cell Carcinoma after Nephrectomy. <i>European Urology</i> , 2017 , 71, 835-836	10.2	
7	Management of upper tract urothelial carcinoma 2018 , 373-382		
6	Re: cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , 2015 , 68, 737	10.2	
5	Reply from Authors re: Giacomo Novara, Vincenzo Ficarra. Is Laparoscopic Cryoablation a Less Invasive and Effective Procedure to Treat Small Renal Masses? <i>Eur Urol</i> 2011;60:444B. <i>European Urology</i> , 2011 , 60, 446-447	10.2	
4	Risk stratification of high-grade Ta, CIS, and T1 urothelial carcinoma of the bladder18-25		
3	Clinical Case Discussion: Kidney Cancer in Transplanted Kidney: The Interdisciplinary Nephrologic-Urologic View. <i>European Urology Focus</i> , 2016 , 2, 223-224	5.1	
2	Therapeutic rationale of targeting BCG and immune checkpoints in non-muscle-invasive bladder cancer: Is this the Future?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 343-345	2.8	
1	Screening programs for renal cell carcinoma: a systematic review by the EAU young academic urologists renal cancer working group.. <i>World Journal of Urology</i> , 2022 , 1	4	